ID   ACVL1_HUMAN             Reviewed;         503 AA.
AC   P37023; A6NGA8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   05-OCT-2010, entry version 121.
DE   RecName: Full=Serine/threonine-protein kinase receptor R3;
DE            Short=SKR3;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 1;
DE            Short=ALK-1;
DE   AltName: Full=TGF-B superfamily receptor type I;
DE            Short=TSR-I;
DE   Flags: Precursor;
GN   Name=ACVRL1; Synonyms=ACVRLK1, ALK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   MEDLINE=93390967; PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J.,
RA   Toyoshima H., Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface
RT   receptors with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=94061985; PubMed=8242742; DOI=10.1016/0092-8674(93)90488-C;
RA   Attisano L., Carcamo J., Ventura F., Weis F.M., Massague J.,
RA   Wrana J.L.;
RT   "Identification of human activin and TGF beta type I receptors that
RT   form heteromeric kinase complexes with type II receptors.";
RL   Cell 75:671-680(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HHT2 CYS-50; GLN-67;
RP   ILE-333; TRP-374 AND THR-424.
RX   MEDLINE=97388752; PubMed=9245985;
RA   Berg J.N., Gallione C.J., Stenzel T.T., Johnson D.W., Allen W.P.,
RA   Schwartz C.E., Jackson C.E., Porteous M.E.M., Marchuk D.A.;
RT   "The activin receptor-like kinase 1 gene: genomic structure and
RT   mutations in hereditary hemorrhagic telangiectasia type 2.";
RL   Am. J. Hum. Genet. 61:60-67(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   VARIANTS HHT2 SER-232 DEL; ARG-376 AND GLN-411.
RX   MEDLINE=96225446; PubMed=8640225; DOI=10.1038/ng0696-189;
RA   Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I.,
RA   Yoon S.-J., Stenzel T.T., Speer M., Pericak-Vance M.A., Diamond A.,
RA   Guttmacher A.E., Jackson C.E., Attisano L., Kucherlapati R.,
RA   Porteous M.E.M., Marchuk D.A.;
RT   "Mutations in the activin receptor-like kinase 1 gene in hereditary
RT   haemorrhagic telangiectasia type 2.";
RL   Nat. Genet. 13:189-194(1996).
RN   [8]
RP   VARIANTS HHT2 TYR-51; TRP-77 AND ASP-96.
RX   PubMed=10694922;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:2<137::AID-HUMU15>3.3.CO;2-D;
RA   Klaus D.J., Gallione C.J., Anthony K., Yeh E.Y., Yu J., Lux A.,
RA   Johnson D.W., Marchuk D.A.;
RT   "Novel missense and frameshift mutations in the activin receptor-like
RT   kinase-1 gene in hereditary hemorrhagic telangiectasia.";
RL   Hum. Mutat. 12:137-137(1998).
RN   [9]
RP   VARIANTS HHT2 GLY-48-49-ALA DELINS EP; CYS-50; SER-232 DEL; ILE-333;
RP   TYR-344 AND ASP-407.
RX   PubMed=10767348; DOI=10.1093/hmg/9.8.1227;
RA   Abdalla S.A., Pece-Barbara N., Vera S., Tapia E., Paez E.,
RA   Bernabeu C., Letarte M.;
RT   "Analysis of ALK-1 and endoglin in newborns from families with
RT   hereditary hemorrhagic telangiectasia type 2.";
RL   Hum. Mol. Genet. 9:1227-1237(2000).
RN   [10]
RP   VARIANTS HHT2 TRP-374 AND ASN-398.
RX   PubMed=11170071;
RX   DOI=10.1002/1096-8628(20010201)98:4<298::AID-AJMG1093>3.0.CO;2-K;
RA   Kjeldsen A.D., Brusgaard K., Poulsen L., Kruse T., Rasmussen K.,
RA   Green A., Vase P.;
RT   "Mutations in the ALK-1 gene and the phenotype of hereditary
RT   hemorrhagic telangiectasia in two large Danish families.";
RL   Am. J. Med. Genet. 98:298-302(2001).
RN   [11]
RP   VARIANTS HHT2 ASP-254 DEL; TRP-411 AND TRP-484.
RX   PubMed=11484689; DOI=10.1056/NEJM200108023450503;
RA   Trembath R.C., Thomson J.R., Machado R.D., Morgan N.V., Atkinson C.,
RA   Winship I., Simonneau G., Galie N., Loyd J.E., Humbert M.,
RA   Nichols W.C., Berg J., Manes A., McGaughran J., Pauciulo M.,
RA   Wheeler L., Morrell N.W.;
RT   "Clinical and molecular genetic features of pulmonary hypertension in
RT   patients with hereditary hemorrhagic telangiectasia.";
RL   N. Engl. J. Med. 345:325-334(2001).
RN   [12]
RP   VARIANTS HHT2 ALA-179; ASP-211; TYR-344; TRP-374; GLN-374; SER-399;
RP   GLN-411 AND THR-487, AND CHARACTERIZATION OF VARIANTS HHT2 CYS-50;
RP   GLN-67; TRP-77; ALA-179; ASP-211; SER-232 DEL; ASP-254 DEL; ILE-333;
RP   TYR-344; GLN-374; LEU-378; GLN-411 AND THR-487.
RX   PubMed=14684682; DOI=10.1136/jmg.40.12.865;
RA   Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J.,
RA   Machado R.D., Elliott C.G., Robbins I.M., Olschewski H.,
RA   McLaughlin V., Gruenig E., Kermeen F., Halme M.,
RA   Raeisaenen-Sokolowski A., Laitinen T., Morrell N.W., Trembath R.C.;
RT   "Molecular and functional analysis identifies ALK-1 as the predominant
RT   cause of pulmonary hypertension related to hereditary haemorrhagic
RT   telangiectasia.";
RL   J. Med. Genet. 40:865-871(2003).
RN   [13]
RP   ERRATUM.
RA   Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J.,
RA   Machado R.D., Elliott C.G., Robbins I.M., Olschewski H.,
RA   McLaughlin V., Gruenig E., Kermeen F., Halme M.,
RA   Raeisaenen-Sokolowski A., Laitinen T., Morrell N.W., Trembath R.C.;
RL   J. Med. Genet. 41:576-576(2004).
RN   [14]
RP   VARIANTS HHT2 ARG-48; LYS-215; ARG-223; ARG-229; SER-233 DEL; PHE-285;
RP   PRO-306; TYR-314; PRO-337; PRO-347; GLN-374; VAL-376; LYS-379;
RP   GLY-397; TRP-411; PRO-411; GLN-411; LEU-425; LEU-479; VAL-482 AND
RP   TRP-484.
RX   PubMed=15024723; DOI=10.1002/humu.20017;
RG   French Rendu-Osler network;
RA   Lesca G., Plauchu H., Coulet F., Lefebvre S., Plessis G., Odent S.,
RA   Riviere S., Leheup B., Goizet C., Carette M.-F., Cordier J.-F.,
RA   Pinson S., Soubrier F., Calender A., Giraud S.;
RT   "Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary
RT   hemorrhagic telangiectasia in France.";
RL   Hum. Mutat. 23:289-299(2004).
RN   [15]
RP   VARIANTS HHT2 TRP-67; TRP-374; LYS-379; ASP-407; TRP-411; VAL-425 AND
RP   PHE-425 DEL.
RX   PubMed=15712270; DOI=10.1002/humu.9311;
RA   Kuehl H.K.A., Caselitz M., Hasenkamp S., Wagner S., El-Harith E.-H.A.,
RA   Manns M.P., Stuhrmann M.;
RT   "Hepatic manifestation is associated with ALK1 in hereditary
RT   hemorrhagic telangiectasia: identification of five novel ALK1 and one
RT   novel ENG mutations.";
RL   Hum. Mutat. 25:320-320(2005).
CC   -!- FUNCTION: On ligand binding, forms a receptor complex consisting
CC       of two type II and two type I transmembrane serine/threonine
CC       kinases. Type II receptors phosphorylate and activate type I
CC       receptors which autophosphorylate, then bind and activate SMAD
CC       transcriptional regulators. Receptor for TGF-beta. May bind
CC       activin as well.
CC   -!- CATALYTIC ACTIVITY: ATP + [receptor-protein] = ADP + [receptor-
CC       protein] phosphate.
CC   -!- COFACTOR: Magnesium or manganese (By similarity).
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- DISEASE: Defects in ACVRL1 are the cause of hereditary hemorrhagic
CC       telangiectasia type 2 (HHT2) [MIM:600376]; also known as Osler-
CC       Rendu-Weber syndrome 2 (ORW2). HHT2 is an autosomal dominant
CC       multisystemic vascular dysplasia, characterized by recurrent
CC       epistaxis, muco-cutaneous telangiectases, gastro-intestinal
CC       hemorrhage, and pulmonary, cerebral and hepatic arteriovenous
CC       malformations; all secondary manifestations of the underlying
CC       vascular dysplasia.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily.
CC   -!- SIMILARITY: Contains 1 GS domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ACVRL1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z22533; CAA80255.1; -; mRNA.
DR   EMBL; L17075; AAA16160.1; -; mRNA.
DR   EMBL; U77713; AAB61900.1; -; Genomic_DNA.
DR   EMBL; U77707; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77708; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77709; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77710; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77711; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77712; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; AC025259; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471111; EAW58213.1; -; Genomic_DNA.
DR   EMBL; BC042637; AAH42637.1; -; mRNA.
DR   IPI; IPI00293271; -.
DR   PIR; A49431; A49431.
DR   RefSeq; NP_000011.2; -.
DR   RefSeq; NP_001070869.1; -.
DR   UniGene; Hs.591026; -.
DR   PDB; 3MY0; X-ray; 2.65 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=195-497.
DR   PDBsum; 3MY0; -.
DR   ProteinModelPortal; P37023; -.
DR   SMR; P37023; 172-493.
DR   DIP; DIP-423N; -.
DR   DIP; DIP-5938N; -.
DR   STRING; P37023; -.
DR   PhosphoSite; P37023; -.
DR   PRIDE; P37023; -.
DR   Ensembl; ENST00000267008; ENSP00000267008; ENSG00000139567.
DR   Ensembl; ENST00000388922; ENSP00000373574; ENSG00000139567.
DR   GeneID; 94; -.
DR   KEGG; hsa:94; -.
DR   UCSC; uc001rzj.1; human.
DR   CTD; 94; -.
DR   GeneCards; GC12P052332; -.
DR   H-InvDB; HIX0026394; -.
DR   HGNC; HGNC:175; ACVRL1.
DR   HPA; HPA007041; -.
DR   MIM; 600376; phenotype.
DR   MIM; 601284; gene.
DR   Orphanet; 422; Idiopathic and/or familial pulmonary arterial hypertension.
DR   Orphanet; 774; Rendu-Osler-Weber disease.
DR   PharmGKB; PA24496; -.
DR   eggNOG; prNOG17435; -.
DR   HOGENOM; HBG314718; -.
DR   HOVERGEN; HBG054502; -.
DR   InParanoid; P37023; -.
DR   OMA; WHVRRRQ; -.
DR   OrthoDB; EOG983GQ0; -.
DR   BRENDA; 2.7.10.2; 247.
DR   BRENDA; 2.7.11.30; 247.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   NextBio; 355; -.
DR   ArrayExpress; P37023; -.
DR   Bgee; P37023; -.
DR   CleanEx; HS_ACVRL1; -.
DR   Genevestigator; P37023; -.
DR   GermOnline; ENSG00000139567; Homo sapiens.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005887; C:integral to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0048185; F:activin binding; IDA:UniProtKB.
DR   GO; GO:0016361; F:activin receptor activity, type I; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IPI:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IMP:HGNC.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:HGNC.
DR   GO; GO:0010596; P:negative regulation of endothelial cell mig...; IDA:BHF-UCL.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:HGNC.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045941; P:positive regulation of transcription; IDA:HGNC.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IDA:HGNC.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:HGNC.
DR   GO; GO:0007179; P:transforming growth factor beta receptor si...; IDA:HGNC.
DR   GO; GO:0035313; P:wound healing, spreading of epidermal cells; IMP:HGNC.
DR   InterPro; IPR000333; Activin_II_recpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR003605; TGF_beta_rcpt_GS.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Disease mutation;
KW   Glycoprotein; Kinase; Magnesium; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Serine/threonine-protein kinase; Signal; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL        1     21       Potential.
FT   CHAIN        22    503       Serine/threonine-protein kinase receptor
FT                                R3.
FT                                /FTId=PRO_0000024420.
FT   TOPO_DOM     22    118       Extracellular (Potential).
FT   TRANSMEM    119    141       Helical; (Potential).
FT   TOPO_DOM    142    503       Cytoplasmic (Potential).
FT   DOMAIN      172    201       GS.
FT   DOMAIN      202    492       Protein kinase.
FT   NP_BIND     208    216       ATP (By similarity).
FT   ACT_SITE    330    330       Proton acceptor (By similarity).
FT   BINDING     229    229       ATP (By similarity).
FT   MOD_RES     155    155       Phosphoserine (By similarity).
FT   CARBOHYD     98     98       N-linked (GlcNAc...) (Potential).
FT   VARIANT      48     49       GA -> EP (in HHT2).
FT                                /FTId=VAR_026784.
FT   VARIANT      48     48       G -> R (in HHT2).
FT                                /FTId=VAR_026785.
FT   VARIANT      50     50       W -> C (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum).
FT                                /FTId=VAR_006204.
FT   VARIANT      51     51       C -> Y (in HHT2).
FT                                /FTId=VAR_006205.
FT   VARIANT      67     67       R -> Q (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum).
FT                                /FTId=VAR_006206.
FT   VARIANT      67     67       R -> W (in HHT2).
FT                                /FTId=VAR_026786.
FT   VARIANT      77     77       C -> W (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum).
FT                                /FTId=VAR_006207.
FT   VARIANT      96     96       N -> D (in HHT2).
FT                                /FTId=VAR_006208.
FT   VARIANT     179    179       D -> A (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately).
FT                                /FTId=VAR_026787.
FT   VARIANT     211    211       G -> D (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum;
FT                                dbSNP:rs28936687).
FT                                /FTId=VAR_026788.
FT   VARIANT     215    215       E -> K (in HHT2).
FT                                /FTId=VAR_026789.
FT   VARIANT     223    223       G -> R (in HHT2).
FT                                /FTId=VAR_026790.
FT   VARIANT     229    229       K -> R (in HHT2).
FT                                /FTId=VAR_026791.
FT   VARIANT     232    232       Missing (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately).
FT                                /FTId=VAR_006209.
FT   VARIANT     233    233       Missing (in HHT2).
FT                                /FTId=VAR_026792.
FT   VARIANT     245    245       I -> N (in dbSNP:rs1804508).
FT                                /FTId=VAR_011717.
FT   VARIANT     254    254       Missing (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum).
FT                                /FTId=VAR_026793.
FT   VARIANT     285    285       L -> F (in HHT2).
FT                                /FTId=VAR_026794.
FT   VARIANT     306    306       A -> P (in HHT2).
FT                                /FTId=VAR_026795.
FT   VARIANT     314    314       H -> Y (in HHT2).
FT                                /FTId=VAR_026796.
FT   VARIANT     333    333       S -> I (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum).
FT                                /FTId=VAR_006210.
FT   VARIANT     337    337       L -> P (in HHT2).
FT                                /FTId=VAR_026797.
FT   VARIANT     344    344       C -> Y (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum;
FT                                dbSNP:rs28936688).
FT                                /FTId=VAR_026798.
FT   VARIANT     347    347       A -> P (in HHT2).
FT                                /FTId=VAR_026799.
FT   VARIANT     374    374       R -> Q (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum).
FT                                /FTId=VAR_026800.
FT   VARIANT     374    374       R -> W (in HHT2; dbSNP:rs28936401).
FT                                /FTId=VAR_006211.
FT   VARIANT     376    376       M -> R (in HHT2; dbSNP:rs28936399).
FT                                /FTId=VAR_006212.
FT   VARIANT     376    376       M -> V (in HHT2).
FT                                /FTId=VAR_026801.
FT   VARIANT     378    378       P -> L (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum).
FT                                /FTId=VAR_026802.
FT   VARIANT     379    379       E -> K (in HHT2).
FT                                /FTId=VAR_026803.
FT   VARIANT     397    397       D -> G (in HHT2).
FT                                /FTId=VAR_026804.
FT   VARIANT     398    398       I -> N (in HHT2; dbSNP:rs28936400).
FT                                /FTId=VAR_026805.
FT   VARIANT     399    399       W -> S (in HHT2; dbSNP:rs28936402).
FT                                /FTId=VAR_026806.
FT   VARIANT     407    407       E -> D (in HHT2).
FT                                /FTId=VAR_026807.
FT   VARIANT     411    411       R -> P (in HHT2).
FT                                /FTId=VAR_026808.
FT   VARIANT     411    411       R -> Q (in HHT2; retained in the cell
FT                                cytoplasm in the endoplasmic reticulum;
FT                                dbSNP:rs28936398).
FT                                /FTId=VAR_006213.
FT   VARIANT     411    411       R -> W (in HHT2).
FT                                /FTId=VAR_026809.
FT   VARIANT     424    424       P -> T (in HHT2).
FT                                /FTId=VAR_006214.
FT   VARIANT     425    425       F -> L (in HHT2).
FT                                /FTId=VAR_026810.
FT   VARIANT     425    425       F -> V (in HHT2).
FT                                /FTId=VAR_026811.
FT   VARIANT     425    425       Missing (in HHT2).
FT                                /FTId=VAR_026812.
FT   VARIANT     479    479       R -> L (in HHT2).
FT                                /FTId=VAR_026813.
FT   VARIANT     482    482       A -> V (in HHT2).
FT                                /FTId=VAR_026814.
FT   VARIANT     484    484       R -> W (in HHT2).
FT                                /FTId=VAR_026815.
FT   VARIANT     487    487       K -> T (in HHT2; mutant protein is
FT                                capable of targeting the cell surface
FT                                appropriately).
FT                                /FTId=VAR_026816.
FT   CONFLICT    172    172       S -> T (in Ref. 1; CAA80255).
SQ   SEQUENCE   503 AA;  56124 MW;  074522AA802325DD CRC64;
     MTLGSPRKGL LMLLMALVTQ GDPVKPSRGP LVTCTCESPH CKGPTCRGAW CTVVLVREEG
     RHPQEHRGCG NLHRELCRGR PTEFVNHYCC DSHLCNHNVS LVLEATQPPS EQPGTDGQLA
     LILGPVLALL ALVALGVLGL WHVRRRQEKQ RGLHSELGES SLILKASEQG DSMLGDLLDS
     DCTTGSGSGL PFLVQRTVAR QVALVECVGK GRYGEVWRGL WHGESVAVKI FSSRDEQSWF
     RETEIYNTVL LRHDNILGFI ASDMTSRNSS TQLWLITHYH EHGSLYDFLQ RQTLEPHLAL
     RLAVSAACGL AHLHVEIFGT QGKPAIAHRD FKSRNVLVKS NLQCCIADLG LAVMHSQGSD
     YLDIGNNPRV GTKRYMAPEV LDEQIRTDCF ESYKWTDIWA FGLVLWEIAR RTIVNGIVED
     YRPPFYDVVP NDPSFEDMKK VVCVDQQTPT IPNRLAADPV LSGLAQMMRE CWYPNPSARL
     TALRIKKTLQ KISNSPEKPK VIQ
//
